A comprehensive review finds that GPC3-targeted immunotherapies including peptide vaccines show promise for preventing liver cancer recurrence after surgery, but have not yet demonstrated strong results against advanced tumors in clinical trials.
Bench to bedside — and backThe GPC3 peptide vaccine reached first-in-human clinical trials, but advanced cancer results lagged preclinical data — highlighting the need for reverse translation research
What the researchers found
GPC3 is confirmed as an ideal cancer antigen for hepatocellular carcinoma (HCC) immunotherapy due to its high expression on tumor cells and limited expression in normal adult tissues. The GPC3 peptide vaccine developed by the authors has progressed from preclinical studies through first-in-human clinical trials.
In resectable HCC, the combination of immune checkpoint inhibitors and GPC3-targeted cancer vaccines appears promising as prophylactic adjuvant therapy to prevent recurrence. However, in advanced HCC, clinical trials across multiple modalities (peptide vaccines, antibody therapy, CAR-T/TCR-T cell therapy) have not demonstrated sufficient anti-tumor efficacy — a disconnect from the encouraging preclinical data that the field must address through reverse translation research.
Why it matters
Liver cancer (HCC) is among the deadliest cancers worldwide, and treatment options for advanced disease remain limited. GPC3's tumor-specific expression makes it one of the most promising targets for cancer immunotherapy, and the fact that a peptide vaccine has already reached human clinical trials demonstrates real translational progress. Understanding why these therapies work better early in the disease could reshape how liver cancer patients receive treatment.
How the study worked
This is a comprehensive review article from researchers with direct experience developing and clinically testing GPC3 peptide vaccines. They surveyed the landscape of GPC3-targeting immunotherapies by focusing on clinical trial results across multiple treatment modalities: peptide vaccines, mRNA vaccines, antibody therapy, and chimeric antigen receptor (CAR) and T-cell receptor (TCR) engineered T-cell therapies for hepatocellular carcinoma.
What this study cannot tell us
As a review article, this paper synthesizes existing evidence rather than presenting new data. The authors are developers of the GPC3 peptide vaccine, which could introduce bias toward their therapeutic approach. The review focuses primarily on HCC and may not fully represent GPC3-targeting efforts in other cancer types where GPC3 is also expressed.
How to read the evidence
This is a review article synthesizing evidence from preclinical studies and clinical trials. While not primary research, it provides expert analysis from researchers who developed and tested the GPC3 peptide vaccine, offering an authoritative overview of the field.
When this study was published
Published in 2024, this review captures the most current state of GPC3-targeted immunotherapy including recent clinical trial results and emerging approaches like mRNA vaccines and CAR-T therapies.
The bigger picture
This review sits at the intersection of peptide vaccine development and precision oncology. GPC3-targeted therapies represent one of the most advanced peptide vaccine programs in cancer, having progressed all the way to human trials. The honest assessment that advanced-disease results have been disappointing is important — it signals the field's recognition that better patient selection, combination strategies, and understanding of the tumor microenvironment are needed to unlock the full potential of peptide-based cancer immunotherapy.
Questions still open
- What specific factors in the tumor microenvironment prevent GPC3-targeted therapies from working in advanced liver cancer?
- Could combining GPC3 peptide vaccines with immune checkpoint inhibitors overcome the efficacy gap seen in advanced disease?
- Would GPC3-targeted therapies work better in other GPC3-expressing cancers beyond hepatocellular carcinoma?
Common questions
What is glypican-3 and why is it a good cancer target?
Why do GPC3-targeted therapies work better after surgery than in advanced cancer?
Read the original research
Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy.
Expert opinion on therapeutic targets, 28(10), 895-909
Citation
Couzinet, Arnaud; Suzuki, Toshihiro; Nakatsura, Tetsuya. (2024). Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy.. Expert opinion on therapeutic targets, 28(10), 895-909. https://doi.org/10.1080/14728222.2024.2416975